Bone Biologics Corp. (BBLG)
0.3948
-0.01
(-2.66%)
USD |
NASDAQ |
Oct 23, 16:00
0.3917
0.00 (0.00%)
After-Hours: 20:00
Bone Biologics Enterprise Value : -3.317M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | -3.317M |
| October 22, 2026 | -3.298M |
| October 21, 2026 | -3.271M |
| October 20, 2026 | -3.253M |
| October 19, 2026 | -3.289M |
| October 16, 2026 | -3.317M |
| October 15, 2026 | -3.330M |
| October 14, 2026 | -3.281M |
| October 13, 2026 | -3.253M |
| October 12, 2026 | -3.208M |
| October 09, 2026 | -3.186M |
| October 08, 2026 | -3.182M |
| October 07, 2026 | -3.149M |
| October 06, 2026 | -3.164M |
| October 05, 2026 | -3.153M |
| October 02, 2026 | -3.171M |
| October 01, 2026 | -3.172M |
| September 30, 2026 | -3.133M |
| September 29, 2026 | -3.133M |
| September 28, 2026 | -3.133M |
| September 25, 2026 | -3.134M |
| September 24, 2026 | -3.142M |
| September 23, 2026 | -3.115M |
| September 22, 2026 | -3.154M |
| September 21, 2026 | -3.171M |
| Date | Value |
|---|---|
| September 18, 2026 | -3.092M |
| September 17, 2026 | -3.127M |
| September 16, 2026 | -3.058M |
| September 15, 2026 | -3.054M |
| September 14, 2026 | -3.054M |
| September 11, 2026 | -3.035M |
| September 10, 2026 | -3.016M |
| September 09, 2026 | -3.029M |
| September 08, 2026 | -3.018M |
| September 04, 2026 | -3.003M |
| September 03, 2026 | -3.022M |
| September 02, 2026 | -3.035M |
| September 01, 2026 | -3.012M |
| August 31, 2026 | -2.987M |
| August 28, 2026 | -2.918M |
| August 27, 2026 | -2.918M |
| August 26, 2026 | -2.917M |
| August 25, 2026 | -2.937M |
| August 24, 2026 | -2.932M |
| August 21, 2026 | -2.898M |
| August 20, 2026 | -2.936M |
| August 19, 2026 | -2.873M |
| August 18, 2026 | -2.867M |
| August 17, 2026 | -2.837M |
| August 14, 2026 | -2.846M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 7.963B |
| Oncolytics Biotech, Inc. | 58.94M |
| Sangamo Therapeutics, Inc. | 39.39M |
| Sarepta Therapeutics, Inc. | 2.130B |
| Anixa Biosciences, Inc. | 88.45M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -0.7737M |
| Total Expenses (Quarterly) | 0.7737M |
| EPS Diluted (Quarterly) | -0.4306 |
| Earnings Yield | -407.8% |
| Normalized Earnings Yield | -408.00 |